Nyxoah S.A. (NYXH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

Market Cap

$164.98M

MomentumView details →

1D Return

−7.95%

YTD Return

−63.48%

RSI (14)

56.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

Market Cap

$164.98M

RSI (14)

56.0

MomentumView details →

1D Return

−7.95%

YTD Return

−63.48%

SummaryUpdated Jun 1, 2026

Nyxoah S.A. (NASDAQ:NYXH) is a Belgian medical technology company founded in 2009 and headquartered in Mont-Saint-Guibert, Belgium. The company went public on NASDAQ in April 2021, focusing on developing innovative solutions for sleep-disordered breathing conditions. Nyxoah has established itself as a challenger in the hypoglossal nerve stimulation market, primarily competing against established players like Inspire Medical Systems. The company has achieved commercial success in Europe, particularly Germany, and is preparing for its U.S. market launch following anticipated FDA approval in early 2025.

Ask drillr about Nyxoah S.A. →

ProfitabilityView details →

Gross Margin

51.31%

Net Margin

−434.72%

EBITDA Margin

−341.10%

ROE (TTM)

−118.49%

ROA (TTM)

−58.46%

Asset Turnover

0.17x

GrowthView details →

Revenue YoY

+359.21%

EPS YoY

−2.84%

FCF YoY

−15.45%

Revenue CAGR 3Y

+48.11%

EPS CAGR 3Y

−30.39%

EBITDA YoY

−8.54%

EarningsView details →

EPS (Actual)

−$0.67

EPS Surprise

−42.55%

Beats (12Q)

1/12

Next Q EPS Est

−$0.39

Avg Surprise (4Q)

−12.03%

Rev Surprise

1.49%

Capital & dividendView details →

Debt/Equity

0.63x

Current Ratio

2.38x

Quick Ratio

2.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

22.65M

Net Income (TTM)

−98.48M

Op. CF (TTM)

−71.81M

Next earningsNov 5, 2026 →

Latest newsMore news →

Nyxoah reported financial and operating results for the second quarter and first half of 2026, with U.S. net revenue of €5.2 million and global net revenue of €7.7 million for Q2 2026.30d ago

Nyxoah announced the U.S. launch of its Genio hypoglossal nerve stimulation system.56d ago

Similar companies

KORU Medical Systems, Inc.KRMD Utah Medical Products, Inc.UTMD Pro-Dex, Inc.PDEX OraSure Technologies, Inc.OSUR Kelfred Holdings Limited01134.HK Microbot Medical Inc.MBOT Find similar companies →

Latest newsMore news →

Nyxoah reported financial and operating results for the second quarter and first half of 2026, with U.S. net revenue of €5.2 million and global net revenue of €7.7 million for Q2 2026.30d ago Nyxoah announced the U.S. launch of its Genio hypoglossal nerve stimulation system.56d ago Nyxoah SA's Genio hypoglossal nerve stimulation therapy won the Prix Galien UK 2026 Award for Best Medical Technology at a ceremony in London.81d ago